Merck dives even further into cytokine research as deal spree continues

Merck’s new leadership hasn’t been shy about its desire to spend, agreeing to drop $11.5 billion on a new biotech and promising to dole out more as the expiration date on the company’s money machine slowly approaches.

On Monday, CEO Robert Davis and R&D chief Dean Li added...

Click to view original post